Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
Novavax (NASDAQ: NVAX) has announced improved terms for its collaboration and license agreement with Takeda for Nuvaxovid®, their protein-based COVID-19 vaccine, in Japan. The amended agreement includes enhanced financial terms such as an upfront payment, payment for the 2024/2025 season, and annual milestone payments tied to regulatory approvals. Additionally, Novavax will receive royalties on net sales for each season moving forward.
The agreement ensures continued availability of Nuvaxovid®, a non-mRNA COVID-19 vaccine, in Japan - the world's third-largest pharmaceutical market. According to CEO John C. Jacobs, this strengthened partnership validates Novavax's technology platform and Matrix-M® adjuvant while positioning the company as a partner of choice.
Novavax (NASDAQ: NVAX) ha annunciato condizioni migliorate per il suo accordo di collaborazione e licenza con Takeda riguardante Nuvaxovid®, il loro vaccino COVID-19 a base proteica, in Giappone. L'accordo modificato include termini finanziari potenziati come un pagamento anticipato, un pagamento per la stagione 2024/2025 e pagamenti annuali legati a milestone regolatorie. Inoltre, Novavax riceverà royalties sulle vendite nette per ogni stagione futura.
L'accordo garantisce la continua disponibilità di Nuvaxovid®, un vaccino COVID-19 non mRNA, in Giappone, il terzo mercato farmaceutico più grande al mondo. Secondo il CEO John C. Jacobs, questa partnership rafforzata conferma la validità della piattaforma tecnologica di Novavax e dell'adjuvante Matrix-M®, posizionando l'azienda come partner preferenziale.
Novavax (NASDAQ: NVAX) ha anunciado términos mejorados para su acuerdo de colaboración y licencia con Takeda para Nuvaxovid®, su vacuna contra el COVID-19 basada en proteínas, en Japón. El acuerdo enmendado incluye condiciones financieras mejoradas, como un pago inicial, un pago para la temporada 2024/2025 y pagos anuales por hitos vinculados a aprobaciones regulatorias. Además, Novavax recibirá regalías sobre las ventas netas para cada temporada futura.
El acuerdo asegura la disponibilidad continua de Nuvaxovid®, una vacuna contra el COVID-19 no basada en ARNm, en Japón, el tercer mercado farmacéutico más grande del mundo. Según el CEO John C. Jacobs, esta asociación fortalecida valida la plataforma tecnológica de Novavax y el adyuvante Matrix-M®, posicionando a la compañía como un socio preferente.
노바백스(NASDAQ: NVAX)는 일본에서 단백질 기반 COVID-19 백신인 Nuvaxovid®에 대한 다케다와의 협력 및 라이선스 계약 조건을 개선했다고 발표했습니다. 개정된 계약에는 선불금, 2024/2025 시즌에 대한 지급금, 규제 승인에 따른 연간 마일스톤 지급금 등 향상된 재정 조건이 포함되어 있습니다. 또한 노바백스는 앞으로 각 시즌별 순매출에 대해 로열티를 받게 됩니다.
이 계약은 세계에서 세 번째로 큰 제약 시장인 일본에서 mRNA가 아닌 COVID-19 백신인 Nuvaxovid®의 지속적인 공급을 보장합니다. CEO 존 C. 제이콥스에 따르면, 이번 강화된 파트너십은 노바백스의 기술 플랫폼과 Matrix-M® 보조제의 가치를 입증하며, 회사를 선호되는 파트너로 자리매김하게 합니다.
Novavax (NASDAQ : NVAX) a annoncé des conditions améliorées pour son accord de collaboration et de licence avec Takeda concernant Nuvaxovid®, leur vaccin COVID-19 à base de protéines, au Japon. L'accord modifié inclut des conditions financières renforcées telles qu'un paiement initial, un paiement pour la saison 2024/2025, ainsi que des paiements annuels liés à des étapes réglementaires. De plus, Novavax percevra des redevances sur les ventes nettes pour chaque saison à venir.
L'accord garantit la disponibilité continue de Nuvaxovid®, un vaccin COVID-19 non à ARN messager, au Japon, le troisième plus grand marché pharmaceutique mondial. Selon le PDG John C. Jacobs, ce partenariat renforcé valide la plateforme technologique de Novavax et l'adjuvant Matrix-M®, positionnant ainsi l'entreprise comme un partenaire de choix.
Novavax (NASDAQ: NVAX) hat verbesserte Bedingungen für seine Kooperations- und Lizenzvereinbarung mit Takeda für Nuvaxovid®, ihren proteinbasierten COVID-19-Impfstoff, in Japan bekanntgegeben. Die geänderte Vereinbarung umfasst verbesserte finanzielle Konditionen wie eine Vorauszahlung, eine Zahlung für die Saison 2024/2025 sowie jährliche Meilensteinzahlungen, die an behördliche Zulassungen gebunden sind. Zusätzlich erhält Novavax für jede zukünftige Saison Lizenzgebühren auf den Nettoumsatz.
Die Vereinbarung sichert die fortgesetzte Verfügbarkeit von Nuvaxovid®, einem nicht mRNA-basierten COVID-19-Impfstoff, in Japan, dem drittgrößten Pharmamarkt der Welt. Laut CEO John C. Jacobs bestätigt diese gestärkte Partnerschaft die Technologieplattform von Novavax und das Adjuvans Matrix-M® und positioniert das Unternehmen als bevorzugten Partner.
- Improved financial terms including upfront payment and seasonal payments
- Secured ongoing presence in Japan, the world's third-largest pharmaceutical market
- Additional revenue stream through royalties on net sales
- Strengthened strategic partnership with Takeda
- None.
- Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market
- Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will continue to be available in
Japan , the world's third largest pharmaceutical market
"Our ongoing partnership with Takeda is important for Novavax and our strengthened agreement enhances our ability to operate effectively in the Japanese market," said John C. Jacobs, President and Chief Executive Officer, Novavax. "This partnership further validates our cutting-edge technology platform and proprietary Matrix-M® adjuvant and our efforts to become a partner of choice."
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most significant health challenges by leveraging its scientific expertise in vaccines and its cutting-edge technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy is focused on building new and diversified partnerships via the out-licensing of its technology platform and vaccine assets earlier in the development process. These strategic collaborations are fueled by smart investments in a growing early-stage pipeline starting with the Company's core expertise in infectious disease and potentially expanding into other disease areas. Please visit novavax.com and LinkedIn for more information.
Forward-Looking Statements
|Statements herein relating to the future of Novavax, its operating plans and prospects, the possible achievement of additional milestones under the CLA, and our ability to operate effectively in the Japanese market, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, antigenic drift or shift in the SARS-CoV-2 spike protein, challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory authorization for a JN.1 protein-based COVID-19 vaccine or for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax's exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
240-720-7804
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-announces-significantly-improved-terms-for-collaboration-and-license-agreement-with-takeda-for-nuvaxovid-in-japan-302445564.html
SOURCE Novavax, Inc.
FAQ
What are the new terms of NVAX's agreement with Takeda for Nuvaxovid in Japan?
How will the improved Takeda agreement affect Novavax's (NVAX) revenue?
Why is the Japanese market important for Novavax's Nuvaxovid?
What type of COVID-19 vaccine is Novavax's Nuvaxovid?
